跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 12 天前AI 评分15

Satellos Bioscience 提交 6-K,附临床与监管策略投资者电话会公告

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

AI 导读

Satellos Bioscience 向美国证券交易委员会提交了 2026 年 11 月的 6-K 文件。随附公告称,公司将举行投资者电话会,更新 BASECAMP II 期儿科研究的临床与监管策略。

正文

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: 001-43107

SATELLOS BIOSCIENCE INC.
(Translation of registrant's name into English)

15 Allstate Parkway, Suite 600, Markham,
Ontario, Canada L3R 5B4

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [   ]      Form 40-F [ X ]


DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

Exhibit Number Description
   
99.1 Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      SATELLOS BIOSCIENCE INC.    
  (Registrant)
   
  
Date: November 5, 2026     /s/ Elizabeth Williams, CPA, CA    
  Elizabeth Williams, CPA, CA
  Chief Financial Officer
  

来源:SEC EDGAR · 本站存档